According to the Global Cancer Report issued by the World Health Organization (WHO), there are over 10 million new cases of cancer each year and over 7.9 million annual deaths from the disease[@b1]. Serious toxicity is a critical problem for effective chemotherapy because most anticancer agents lack selective efficacy in tumors. Another vital issue is the development of tumor resistance to conventional chemotherapy. Drug resistance, which allows tumors to evade chemotherapeutic agents, has emerged as a major obstacle that limits the efficacy of chemotherapy. The formidable side effects of individual or combined anticancer agents as well as the treatment history and clinical status of the patient must be considered to circumvent the tumor resistance to chemotherapy in clinic. Tumors generally develop significant resistance to repeated treatment with one kind of anticancer agent and then often become resistant to similar or completely different drugs. This mechanism for tumor survival under chemotherapeutic treatment is known as multidrug resistance (MDR). MDR can be intrinsic or acquired through chemotherapeutic drug exposure, and multiple mechanisms are likely to contribute to clinical MDR. Historically, the most significant discovery about MDR was the identification of P-glycoprotein (P-gp)[@b2], which is overexpressed on the plasma membrane of cancer cells with MDR. Following P-gp, other transporters, such as multidrug resistance-associated protein 1 (MRP1)[@b3] and multixenobiotic resistance (MXR)[@b4], are also recognized to relate with drug efflux. In recent years, applications of nanotechnology have shown great promise, with several kinds of nanomedicine entering clinical studies. Although the feasibility and efficacy of reversing drug resistance has been confirmed *in vitro* and *in vivo*, the mechanisms by which to use nanotechnology to circumvent this phenotype have not been clarified or fully explored.

This article introduces nanotechnology-based formulations and possible nanomedical approaches to address MDR in tumors, with a specific focus on the use of nanotechnology in cancer to overcome drug efflux-mediated resistance.

Possible Mechanisms of Drug Efflux-mediated Resistance in Cancer {#s2}
================================================================

The changes that drive antitumor drug resistance include the following: increased activity of drug efflux pump, such as the ATP-binding cassette (ABC) superfamily; decreased drug influx; activation of DNA repair; metabolic modification or detoxification; and altered expression of apoptosis-associated protein Bcl-2[@b5] and tumor suppressor protein p53[@b6],[@b7]. Of these mechanisms, overexpression of ABC transporters is the most frequent. ABC transport molecules are generally expressed on the plasma membrane and on the membranes of cellular vesicles, and they play vital physiologic functions and also affect the pharmacokinetic properties of chemotherapeutics in humans. ABC transporters are transmembrane proteins that use the energy of ATP hydrolysis to shuttle various substrates across the cell membrane. To date, there are 48 known transporters in the ABC family, which are classified into seven different subfamilies (ABC A through ABC G)[@b8]−[@b11] ([Table 1](#cjc-31-02-100-t01){ref-type="table"}). Thirteen ABC transporters contribute to tumor MDR, including P−gp (MDR1/ABCBI), multidrug resistance proteins (MRPs/ABCCs), and breast cancer resistance protein (BCRP/ABCG2), all of which are the most characterized ABC transporters[@b12]. The normal function of ABC transporters as pumps is to extrude toxins and foreign substances out of the cell. P−gp is the best−known membrane pump molecule of the ABC transporters involved in MDR. Human P−gp, a 170 kDa membrane−associated protein containing 1280 amino acids, is able to carry out an ATP−dependent conformational change that moves the intracellular substrates to the exterior of the cell[@b2]. It can transport a broad range of structurally related or unrelated compounds including anticancer drugs out of cells and thereby decrease intracellular accumulation of these compounds. Therefore, P−gp expression can physiologically prevent cytotoxic compounds by pump them out of cells to reduce their intracellular concentration. In patients with tumors, P−gp can efflux various anticancer drugs such as doxorubicin [@b13]--[@b15] and paclitaxel[@b16],[@b17] out of cancer cells. Overexpression of P−gp is a common feature of most acquired MDR in solid tumors[@b18],[@b19]. Other transporters such as MRP1, MRP2, and BCRP also contribute to drug distribution in the human body in cases where P−gp expression is not significantly altered after treatment.

Application of Nanoparticle Delivery Systems to Reverse Drug Efflux-mediated Resistance {#s3}
=======================================================================================

As mentioned above, overexpression of ABC transporters is the broadly known tumor survival mechanism that limits the efficacy of chemotherapeutic agents in clinical cancer treatments. Currently, there are no traditional strategies without serious side effects to completely reverse chemotherapeutic resistance in tumors. Based on their unique physical and biological properties, cancer nanotechnologies developed in recent years offer an unprecedented opportunity for rational delivery of anticancer drugs to solid tumors[@b20],[@b21]. The promise of nanotechnology lies in the ability to engineer customizable nanoscale constructs, which have more controllable surface for different modification, and to accommodate multiple types of payloads, such as cancer chemotherapeutics, chemosensitizers, or molecular imaging agents[@b22],[@b23]. Nanoparticles have been developed to prevent, detect, and treat resistant cancer cells while minimizing serious toxicity in normal cells and improving drug solubility and stability. Nanostructure platforms derive their effectiveness from adequate delivery systems, including polymers, dendrimers, nanoshells, nanotubes, micelles, liposomes, lipid-based nanoparticles, magnetic nanoparticles, and virus nanoparticles. For rigid nanoparticles, the size to support long circulation *in vivo* may not exceed 200 nm, a size that is not achievable with individual molecules alone or with equivalent materials at a larger scale. Nanoscale drug delivery systems in the size range of 10-100 nm penetrate preferentially through the tumor vasculature via the so-called enhanced permeability and retention (EPR) effect [@b24]--[@b26]. Multifunctionalization of hydrophilic nanoparticles can provide a long circulating half-life and prolong the exposure time of chemotherapeutic drugs. These unique properties based on nanostructure effectively increase the intracellular accumulation of anticancer drugs by controllable and efficient release at targeted regions due to their size effect ([Figure 1](#cjc-31-02-100-g001){ref-type="fig"}). Furthermore, properly designed nanoparticles with a targeting element can aim at specific targeting sites actively with the therapeutic payloads to overcome tumor MDR. One example is the use of folate acid as an active target. Nanoparticle with folate acid ligands can bind to folate receptors, which were found to be overexpressed on the surface of drug-resistant tumor cells, to achieve the specific accumulation in tumors. In addition, nanoplatforms offer opportunities to coencapsulate multiple therapeutic agents into a single functional carrier and allow imaging to be combined with drug treatment to monitor therapeutic effects in real time. Efforts to co-administrate drugs with ultrasound and thermosensitive therapy or photodynamic therapy improve the nanoparticle delivery systems for synergistic and comprehensive functions of cancer nanochemotherapy[@b27]--[@b30]. In summary, the advantages of nanoparticle-based drug delivery system include narrow size distribution, low carrier toxicity, enhanced drug solubilization via protecting drugs from efflux, prevention from drug metabolism or excretion before accumulating in tumors, increased drug loading, prolonged drug circulation, specific site targeting, and controlled drug release. Cancer nanotechnology has the potential to reverse tumor MDR in a way that is not achievable with traditional strategies.

###### Demographic and clinical characteristics of the studied population

  Gene           Alias        Subfamily   Location   Gene size (bp)   dN/dS   Transcript   Protein   Main tissue expression   Function                                         Disease                                                                                        
  -------- ----------------- ----------- ---------- ---------------- ------- ------------ --------- ------------------------ ---------- -------------------------------------------------------------------------------------- ---------------------------------------------- -----------------------------------------------------------------------------------------------------------------------
  ABCA1          ABC1           ABC1       9q31.1        147154       0.078     0.048       0.072              1                 1                                            Ubiquitous                                        Cholesterol efflux onto HDL drug resistance                                      Tangier\'s disease, familial hypoapo-proteinemia
  ABCA2          ABC2           ABC1       9q34.3        21689                  0.043       0.030              2                 2                                              Brain                                                         Drug resistance                 
  ABCA3       ABC3, ABCC        ABC1      16p13.3        53974        0.072     0.069       0.072              1                 1                                               Lung                                                     Phospholipid metabolism                                                        Surfactant deficiency in newborns
  ABCA4          ABCR           ABC1       1p21.3        128287       0.151     0.128       0.126              1                 1                                          Photoreceptors                                                N-retinylidene-PE efflux             Stargardt\'s disease/fundusflavimaculatis, retinitis pigmentosa, cone-rod dystrpohy, age-related macular degeneration
  ABCA5                         ABC1      17q24.3        80499        0.132     0.091       0.087              2                 2                                      Muscle, heart, testes                                                                                 
  ABCA6                         ABC1      17q24.3        63169                  0.356       0.282              1                 1                                              Liver                                                                                         
  ABCA7                         ABC1      19p13.3        10347                  0.118       0.130              2                 2                                          Spleen, thymus                                                                                    
  ABCA8                         ABC1      17q24.3        88101        0.256     0.256       0.298              1                 1                               Ovary, heart, skeletal muscle, liver                                                                         
  ABCA9                         ABC1      17q24.3        86155        0.239     0.245       0.271              2                 2                                              Heart                                                                                         
  ABCA10                        ABC1      17q24.3        96808         NA         NA         NA                1                 1                                          Muscle, heart                                                                                     
  ABCA12                        ABC1        2q34         206885       0.113     0.075       0.101              2                 2                                             Stomach                                            Glucosylceramide, other epidermal lipids                               Lamellar ichthyosis type 2 (mild); Harlequin ichthyosis (severe)
  ABCA13                        ABC1       7p12.3        449249       0.397     0.221       0.218              1                 1                                        Low in all tissues                                                                                  
  ABCBI     PGY1, MDR, P-gp      MDR      7p21.12        209617       0.180      0.16       0.145              1                 1              Adrenal, kidney, brain, liver, intestine, testis, gland, uterus, ovary                      Multidrug resistance                                                      Ivermectin sensitivity, digoxin uptake
  ABCB2          TAP1            MDR        6p21          8765        0.016     0.031       0.026              1                 1                                             All cell                                                      Peptide transport                                                                   Immune deficiency
  ABCB3          TAP2            MDR        6p21         16912        0.225     0.204       0.207              2                 2                                             All cell                                                      Peptide transport                                                                   Immune deficiency
  ABCB4      PGY3 or MDR3        MDR      7q21.12        75506        0.152     0.097       0.091              3                 3                                              Liver                                                           PC transport                                  Progressive familial intrahepatic cholestasis-3, intrahepatic cholestasis of pregnancy
  ABCB5                          MDR       7p21.1        108203       0.283     0.212       0.197              1                 1                                            Ubiquitous                                                                                      
  ABCB6         MTABC3           MDR        2q35          9179        0.201     0.134       0.156              1                 1                                           Mitochondria                                                      Iron transport                                                                         Unknown
  ABCB7          ABC7            MDR      Xq21-22        103026       0.215      0.11       0.059              1                 1                                           Mitochondria                                                  Fe/S cluster transport                                                       X-linked sideroblastosis and anemia
  ABCB8          MABC1           MDR       7q36.1        17116        0.135     0.137       0.150              1                 1                                           Mitochondria                                                                                     
  ABCB9                          MDR      12q24.31       46214        0.045     0.036       0.037              4                 3                                              Liver                                                                                         
  ABCB10        MTABC2           MDR      1q42.13        42113        0.100     0.120       0.161              1                 1                                           Mitochondria                                                                                     
  ABCB11     SPGP or BSEP        MDR       2q24.3        108385       0.173     0.212                          1                 1                                         Liver, intestine                                                 Bile salt transport                                                   Progressive familial intrahepatic cholestasis-2
  ABCC1          MRP1          CF/MRP     16p13.12       192840       0.064     0.060       0.062              7                 7                           Lung, testes, intestine, PBMC, kidney, brain                                     Drug resistance                 
  ABCC2      MRP2 or cMOAT     CF/MRP     10q24.2        69011        0.313     0.243       0.180              1                 1                                     Liver, intestine, kidney                                             Organic anion efflux                                                              Dubin-johnson syndrome
  ABCC3          MRP3          CF/MRP     17q21.33       56836        0.169     0.164       0.204              1                 1                    Lung, intestine, liver, kidney, placenta, pancreas, colon                               Drug resistance                 
  ABCC4          MRP4          CF/MRP     13q32.1        281594       0.137     0.099       0.060              1                 1                           Prostate, lung, adrenal gland, ovary, testis                                   Nucleoside transport              
  ABCC5          MRP5          CF/MRP      3q27.1        97956        0.069     0.073       0.053              1                 1                                            Ubiquitous                                                    Nucleoside transport              
  ABCC6          MRP6          CF/MRP     16p13.12       73325        0.098     0.149       0.160              1                 1                                          Kidney, liver                                                   Nucleoside transport                                                             Pseudoxanthoma elasticum
  CFTR           ABCC7         CF/MRP     7q31.31        188699       0.172     0.172       0.238              1                 1                                         Exocrine tissue                                                  Chloride ion channel                                                Cystic fibrosis CBAVD, pancreatitis, bronchiectasis
  ABCC8          SUR1          CF/MRP     11p15.1        84017        0.093     0.045       0.055              1                 1                                             Pancreas                                                    Sulfonylurea receptor                                 Familial persistent hyperinsulinemic hypoglycemia of infancy; AD type 2 diabetes
  ABCC9          SUR2          CF/MRP     12p12.1        135631       0.021     0.039                          3                 3                                          Heart, muscle                                       Regulatory subunit of cardiac K(ATP) channel                                    Dilated cardiomyopathy with ventricular tachycardia
  ABCC10         MRP7          CF/MRP      6p21.1        18675        0.170     0.195       0.171              1                 1          Low in all tissues; a little higher in heart, skeletal, muscle, spleen, liver                                                     
  ABCC11         MRP8          CF/MRP     16q12.1        68267        0.304       NA         NA                2                 3                    Low in all tissues, a little higher in breast, and testis                                                               
  ABCC12         MRP9          CF/MRP     16q12.1        63798        0.200     0.184       0.166              1                 1       Low in all tissues, a little higher in breast, testis, brain, ovary, skeletal muscle                                                 
  ABCC13                                                                                                                                                                                                                                                                      
  ABCD1          ALDP            ALD        Xq28         19846        0.045     0.053       0.058              1                 1                                           Peroxisomes                                                 VLCFA transport regulation                                                            Adrenoleukodystrophy
  ABCD2       ALDL1, ALDR        ALD       12q11         67424        0.085     0.066       0.073              1                 1                                           Peroxisomes                                                                                      
  ABCD3      PXMP1, PMP70        ALD       1p22.1        100072       0.050     0.051       0.058              1                 1                                           Peroxisomes                                                                                      
  ABCD4       PMP69, P70R        ALD      14q24.3        17540        0.188     0.112       0.110              1                 1                                           Peroxisomes                                                                                      
  ABCE1       OABP, RNS41       OABP      4q31.31        30851        0.003     0.061       0.002              1                 1                                      Ovary, testes, spleen                                          Oligoadenylate binding protein         
  ABCF1          ABC50          GCN20      6p21.1        19920        0.022     0.057       0.055              1                 1                                            Ubiquitous                                                                                      
  ABCF2                         GCN20      7q36.1        19395        0.036     0.011       0.010              2                 2                                            Ubiquitous                                                                                      
  ABCF3                         GCN20      3q27.1         7908        0.027     0.030       0.035              1                 1                                            Ubiquitous                                                                                      
  ABCG1       ABC8, White       White     21q22.3        97556        0.012     0.012       0.010              7                 7                                            Ubiquitous                                                   Cholesterol transport?             
  ABCG2     ABCP, MXR, BCRP     White       4q22         66883        0.269     0.206       0.202              1                 1                                    Placenta, intestine, brain                                       Toxin efflux, drug resistance          
  ABCG4         White2          White      11q23         13626        0.026     0.064       0.027              1                 1                                              Liver                                                                                         
  ABCG5         White3          White       2p21         26348        0.302     0.175       0.157              1                 1                                         Liver, intestine                                                   Sterol transport                                                                    Sitosterolemia
  ABCG8                         White       2p21         39503        0.152     0.126       0.206              1                 1                                         Liver, intestine                                                   Sterol transport                                                                    Sitosterolemia

ABC, ATP-binding cassette; HDL, high-density lipoprotein; PGY, P-glucoprotein; MDR, multidrug resistance; MXR, multixenobiotic resistance; MRP, multidrug resistance-associated protein; BCRP, breast cancer resistance protein; TAP, transporter ATP-binding cassette, ATP-binding cassette sub-family B; PC, phosphatidylcholine; MTABC, mitochondrial ATP-binding cassette; SPGP, sister of P-glycoprotein; BSEP, bile salt export pump; MRP, multiple drug resistance protein; PBMC, peripheral blood mononuclear cell; cMOAT, canalicular multispecific organic anion transporter 1; CF, cystic fibrosis; SUR, sulfonylurea receptor; ALD, adrenoleukodystrophy; ALDP, adrenoleukodystrophy protein; ALDR, adrenoleukodystrophy-related protein; PXMP, peroxisomal membrane protein; PMP, putative peroxisomal membrane protein; OABP, ATP-binding cassette, sub-family E; GCN20, ATP-binding cassette sub-family F; CBAVD, congenital bilateral absence of the vas deferens; VLCFA, very long chain fatty acid.

Cancer Nanomedicine for Overcoming Drug Efflux-mediated Resistance {#s4}
==================================================================

An important prerequisite for reversing drug resistance in cancer is achieving a high concentration of the drug in the plasma, a high concentration and long retention time in MDR cancer cells to ensure effective intracellular accumulation. Considering different mechanisms of drug resistance in cancer, nanoparticles are always designed to inhibit or bypass efflux pumps on the membrane or to enhance endocytosis when recognizing MDR tumors. Over 50% of the anticancer drugs used in the clinic today are targeted by P-gp[@b31]. However, P-gp inhibitors do not have specific selectivity and also block the normal function of P-gp. Nanotechnology refines the concept of co-administering anticancer agents and P-gp inhibitors by combining them into a single drug carrier for simultaneous delivery into MDR tumor cells. In a recent review by Gottesman *et al.*[@b32], the strategies for circumventing P-gp-mediated MDR are eloquently categorized as follows: using P-gp inhibitors to block the efflux of cytotoxic agents; using drugs that are not substrates of P-gp; and exploiting the properties of MDR cells, such as receptor overexpression and collateral drug sensitivity. D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS 1000), which functions as an effective inhibitor of P-gp, turned out to be one of the prominent surfactants that enhancing the cytotoxicity of doxorubicin, vinblastine, paclitaxel, and colchicines in G185 cells comparable to that in the parental cells. Reversal of P-gp activity was due to the effect of TPGS 1000 on transport at concentrations even below its critical micelle point of 0.02 wt%. This excipient was evaluated in a phase II clinical trial for drug resistance[@b33]. Pluronic block copolymer (P85) is another important and promising example of a modifying agent for P-gp. Membrane fluidization by P85 treatment led to inhibition of the P-gp ATPase drug efflux system and to interference with metabolic processes. These results indicate that both energy depletion (via decreasing ATP pool necessary for P-gp function) and increased permeability and fluidization of a broad spectrum of drugs are critical factors contributing to the activity of the block copolymer for MDR reversion[@b34],[@b35]. First-generation agents (for example, the calcium channel blocker verapamil) are limited by unacceptable toxicity to normal tissues, whereas second-generation agents (for example, valspodar and biricodar) have better tolerability but are limited by nonspecificity. Third-generation inhibitors (for example, tariquidar XR9576, LY335979, GF120918, 9576, etc.) have high potency and specificity for P-gp. Tariquidar has shown marked effectiveness in early clinical trials. GF120918 has achieved adequate P-gp inhibition *in vivo* without significant side effects[@b36],[@b37]. Taken together, the development of these findings suggests the necessity to consider to combine nanoparticle therapies with P-gp inhibitors.

Recent studies also demonstrated that nucleic acid (DNA, miRNA, siRNA, etc.)-based nanoparticles play a critical role in the modulation of drug resistance in tumors by effectively decreasing MDR1 expression *in vivo*[@b38]--[@b40]. The employed system, which uses siRNA to silence the expression of ABC transporters in combination with an appropriate anticancer drug, is a systemic administration strategy for MDR cells. Meng *et al.*[@b41] successfully achieved dual delivery of doxorubicin (Dox) and P-gp siRNA loaded in mesoporous silica nanoparticles (MSNP). P-gp gene knockdown by siRNA effectively increased the intracellular and intranuclear drug concentration. Similar results were also observed *in vitro* and *in vivo* using RGD peptide (arginine-glycine-aspartic acid)-modified liposomes containing P-gp siRNA or doxorubicin[@b42]. MacDiarmid *et al.* [@b43] provided a dual sequential treatment strategy for drug-resistant tumors with targeted micelles containing siRNA and a cytotoxic drug. First, the resistant tumors were treated with siRNA/shRNA-containing minicells targeted to tumors via bispecific antibodies (BsAb) for 48 h (for siRNA-containing minicells) and 144 h (for shRNA-containing minicells) to achieve substantial knockdown of MDR1. A second wave of treatment with siRNA/shRNA-containing minicells was followed with intravenous administration of BsAb-targeted minicells packaged with cytotoxic drugs to resistant tumor xenografts. Both the sequential and simultaneous approaches were effective and feasible and markedly decreased the doses of cytotoxic drug necessary for eliminating tumors. Injection of anti-MDR1 short hairpin RNA-encoding vectors into tumor cells with intravenous administration of doxorubicin completely reversed the MDR phenotype and inhibited tumor growth[@b44].

![Unique nanoplatforms effectively increase the intracellular accumulation of anticancer drugs by controllable and efficient release at targeted regions.\
These functionalized nanoparticles can be modified with anticancer drugs, image moiety, specific ligands, antibodies, and so on, to fulfill chemotherapy through increasing drug accumulation.](cjc-31-02-100-g001){#cjc-31-02-100-g001}

In addition, some nanomedicines that circumvent MDR in cancer through other targets are being tested in clinical trials ([Table 2](#cjc-31-02-100-t02){ref-type="table"}). These include taxane analogs DJ-927 (phase I/Il)[@b57]--[@b59] and ortataxel (phase II)[@b60],[@b61], as well as BMS-184476 (phase II)[@b62]--[@b64] and RPR 109881A (phase I)[@b65]--[@b67], which were purported to have a broad spectrum of activity both in sensitive and resistant tumor cell lines. Nab-paclitaxel is a novel clinical entity incorporating paclitaxel into an albumin nanoparticle, leading to increased intratumoral concentration and showing with superior response rate, longer time to tumor progression, and prolonged survival as second-line therapy in patients with gynecologic cancers[@b68],[@b69]. EGFR-targeted polymer-blend nanocarriers with a combination of paclitaxel and lonidamine were found to enhance the therapeutic index of both drugs by inhibiting the Warburg effect and promoting mitochondrial binding of pro-apoptotic Bcl-2 protein (via lonidamine), while hyperstabilizing microtubules (via paclitaxel)[@b70].

###### Selected examples of nanoparticles used to overcome drug resistance in cancer treatment evaluated *in vivo* in the past three years

  Nanotransporters                                                                                               Main bioactive element                                               Main Mechanism                          Reference
  ------------------------------------------------------------------------------------- ------------------------------------------------------------------------ --------------------------------------------------------- ---------------
  siRNA, minicells                                                                                                    Doxorubicin                                                     P-gp inhibition                          [@b43]
  Dendrimer phthalocyanine-encapsulated polymeric micelle (DPc/m)-mediated PCI                                        Doxorubicin                                                     P-gp inhibition                          [@b45]
  Poly(D,L-lactide-co-glycolide)                                                                                 Paclitaxel, tariquidar                                               P-gp inhibition                          [@b46]
  Poly(D,L-lactide-co-glyco-lide) nanoparticles                                                            Paclitaxel, *P-gp* targeted siRNA                                          P-gp inhibition                          [@b47]
  Albumin bound nanoparticles                                                                                          Paclitaxel                                 Paditaxel-induced NF-κB pathway that up-regulatesVEGF-A      [@b48]
  Aerosol-OT (AOT)                                                                                                    Doxorubicin                                      Prevents the accumulation of anticancer drugs        [@b49],[@b50]
  Folate receptor-targeting nanoparticle                                                 Heparin-folate-paclitaxel (HFT) backbone with an additional paclitaxel                       P-gp inhibition                          [@b51]
  PLGA nanoparticles                                                                                  Vincristine sulfate, verapamil hydrochloride                       Enhanced permeation and retention effect              [@b52]
  Cationic liposome-polycation-DNA (LPD) and anionic liposome-polycation-DNA (LPD-II)                            Doxorubicin and siRNA                                   Avoid P-gp efflux and increase Dox uptake             [@b53]
  Polymer-blend nanoparticle                                                                                            Ceramide                                           Modulation of the apoptotic threshold               [@b54]
  Albumin bound nanoparticles                                                                                   Rapamycin and perifosine                                 Suppression of the PI3K/Ak1/mTOR pathway              [@b55]
  Fe(3)O(4)-magnetic nanoparticle                                                                                     Daunorubicin                                                   Mdr-1 inhibition                          [@b56]

P-gp, P-glycoprotein; aerosol-OT (AOT), bis-2-ethylhexoxyl sodium sulfosuccinate; PLGA, poly(lactic-co-glycolic acid); VEGF-A, vascular endothelial growth factor A; Dox, doxorubicin; PI3K, phosphoinositide 3-kinase; Akt, protein kinase B; mTOR, mammalian target of rapamycin; Mdr-1, multidrug resistant gene-1.

Future Perspectives {#s5}
===================

MDR is a major impediment to the success of cancer chemotherapy. P-gp is the best known membrane transporter involved in MDR in tumors. Several strategies have been used to address MDR, especially P-gp-mediated drug resistance in tumors. However, clinical success has been limited, largely due to lack of efficacy and/or significant toxicity. To overcome both the dose-limiting side effects of conventional chemotherapeutic agents and the therapeutic failure resulting from MDR, cancer nanotechnology has been developed and shown its ability to target tumors based on their unique physical and biological properties. To date, nanoparticles have been investigated primarily to address P-gp and have been shown to improve anticancer efficacy, indicating that nanomedical strategies might provide a new opportunity to overcome MDR[@b71]. The most predominant advantage of nanomedicine is to deliver and concentrate drugs at the plasma membrane where ABC transporters are located and saturated with extra drugs. In addition, functionalized nanoparticles themselves or their metabolites can also block the function of ABC transporters such as P-gp by direct or indirect interaction and inhibition. The flexibility of nanoparticles with regard to their size and shape increases their potential to enhance drug-loading capacity, stabilize drugs and regulate their release rates, and deliver drugs to targeted sites effectively and specifically. This article provides a glimpse into the nanotechnology-based strategies being developed to overcome drug resistance. To the best of our knowledge, however, there are currently no nano-fomulations for drug delivery aimed at overcoming drug resistance that have been effective in clinical tests. Various nanocarriers for targeted delivery of anticancer drugs have already undergone *in vivo* testing in mouse models ([Table 2](#cjc-31-02-100-t02){ref-type="table"}) and clinical evaluation in humans. With better understanding of the physiologic properties of drug-resistant tumors and enhanced nanomaterial design, there will be more opportunities to develop multifunctional nanostructures for circumventing drug resistance. A safe and effective multifunctional nanosystem could provide a versatile platform to benefit patients with MDR tumors in the future.
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